Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Blood|May 9, 2001
Identification of a leukemic counterpart of the plasmacytoid dendritic cellsL Chaperot, N Bendriss, O Manches, et al.
British Journal of Cancer|October 10, 2007
Intensified dose of cyclophosphamide with G-CSF support versus standard dose combined with platinum in first-line treatment of advanced ovarian cancer a randomised study from the GINECO groupI Ray-Coquard, D Paraiso, J-P Guastalla, et al.
Seminars in Oncology|November 5, 1997
Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II studyE Pujade-Lauraine, J P Guastalla, B Weber, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 30, 1998
Efficacy and safety of the paclitaxel and carboplatin combination in patients with previously treated advanced ovarian carcinoma. A multicenter GINECO (Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens) phase II studyJ P Guastalla, E Pujade-Lauraine, B Weber, et al.
European Journal of Cancer (Oxford, England : 1990)|February 14, 2004
Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancerP Fumoleau, R Largillier, C Clippe, et al.
British Journal of Cancer|February 5, 2009
Gemcitabine-oxaliplatin combination for ovarian cancer resistant to taxane-platinum treatment: a phase II study from the GINECO groupI Ray-Coquard, B Weber, J Cretin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 27, 2016
A phase III trial of exemestane plus bevacizumab maintenance therapy in patients with metastatic breast cancer after first-line taxane and bevacizumab: a GINECO group studyO Trédan, P Follana, I Moullet, et al.
ESMO Open|May 1, 2024
Prognostic value of EndoPredict test in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phase III UNIRAD trialF Penault-Llorca, F Dalenc, S Chabaud, et al.
Pageof 2